I am not too hopeful for newer high soon. We know the good and bad of ASH - Cortes good data, Cortes not so good - rising safety factors. That sums it up.
Maybe a bit from the 30mg cohort, or some 30mg data from a trial makes a good splash. We'll also hear at some point soon, the EPIC data that led to the end of that trial.
And we are left pacing in the waiting room for the FDA decisions.